Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of SPY001, SPY002, SPY003, and combination regimens in ulcerative colitis
jRCT2071260093Not yet recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of SPY001, SPY002 and SPY003 in autoimmune colitis (7 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SPY001SPY002SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071260093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260093.